An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children

Vaccine

Volumn 29, Issue 25, 2011, Pages 4264-4273

  Knuf, Markus ^a,b   Pantazi Chatzikonstantinou, Anna ^c   Pfletschinger, Ulrich ^d   Tichmann Schumann, Irmingard ^e   Maurer, Hartwig ^f   Maurer, Lothar ^g   Fischbach, Thomas ^h   Zinke, Henrike ⁱ   Pankow Culot, Heidemarie ⁱ   Papaevangelou, Vassiliki ^j   Bianco, Veronique ^k   Van der Wielen, Marie ^k   Miller, Jacqueline M ^l  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Children's Hospital   (Germany)

^c General Hospital of Komotini   (Greece)

^d Private   (Germany)

^e Private Practice   (Germany)

^f Private Practice   (Austria)

^g Private Practice   (Germany)

^h Private Practice   (Germany)

ⁱ NONE   (Germany)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

Bactericidal activity; Conjugate vaccine; DTaP HBV IPV Hib combination vaccine; Hexavalent vaccine; Tetravalent meningococcal vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ANOREXIA; ANTIBODY TITER; ARTICLE; CHILD; DIPHTHERIA; DROWSINESS; FEMALE; FEVER; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; INFANT; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; PERTUSSIS; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TETANUS; TODDLER; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 79956193785     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.009     Document Type: Article

References (43)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344:1378-1388.
2. Pelton S.I., Gilmet G.P. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines 2009, 8:717-727.
3. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 31:27-36.
4. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
5. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27:B51-B63.
6. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004, 23:S274-S279.
7. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20:S58-S67.
8. Larrauri A., Cano R., García M., Mateo S.D. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
9. Booy R., Jelfs J., El Bashir H., Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007, 186:108-109.
10. Tsolia M.N., Theodoridou M., Tzanakaki G., Vlachou V., Mostrou G., Stripeli F., et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006, 25:449-456.
11. Swartley J.S., Marfin A.A., Edupuganti S., Liu L.J., Cieslak P., Perkins B., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997, 94:271-276.
12. Aguilera J., Perrocheau A., Meffre C., Hahné S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 2002, 8:761-767.
13. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002;77:331-9.
14. MENACTRA (meningococcal groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine). Product information. October 2007 Sanofi Pasteur. [Internet]. Available from [accessed 13 October 2010]. https://www.vaccineshoppe.com/image.cfm?pi=589-05%26image_type=product_pdf.
15. MENVEO® Meningococcal Group A, C, W135 and Y conjugate Vaccine Summary of Product Characteristics. Novartis Vaccines. [Internet]. Available from: [accessed 13 October 2010]. http://www.medicines.org.uk/emc/medicine/22866/SPC/Menveo%20Group%20A,%20C,%20W135%20and%20Y%20conjugate%20vaccine.
16. Knuf M., Kieninger-Baum D., Habermehl P., Muttonen P., Maurer H., Vink P., et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010, 28:744-753.
17. Vesikari T., Karvonen A., Lindblad N., Poolman J., Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 1-2 year-olds. 27th annual meeting of the European Society for Paediatric Infectious Diseases 2009, [Abstract].
18. Vesikari T., Karvonen A., Bianco V., Van der Wielen M., Miller J. Immunogenicity and safety of the co-administration of the MenACWY-TT conjugate vaccine with MMRV in toddlers. 28th annual meeting of the European Society for Paediatric Infectious Diseases 2010, [Abstract].
19. Vesikari T., Karvonen A., Bianco V., Van der Wielen M., Miller J. The meningococcal tetravalent tetanus toxoid conjugate vaccine (MenACWY-TT) is immunogenic and has an acceptable safety profile in toddlers 12-23 month. 28th annual meeting of the European Society for Paediatric Infectious Diseases 2010, [Abstract].
20. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4(March):156-167.
21. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
22. Centers for Disease Control and Prevention. Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006;55:1016-7.
23. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983, 11:137-144.
24. Camargo M.E., Silveira L., Furuta J.A., Oliveira E.P., Germek O.A. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984, 20:772-774.
25. Granström M., Thorén M., Blennow M., Tiru M., Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987, 6:18-21.
26. Karpinski K.F., Hayward S., Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987, 103:189-194.
27. Mast E., Mahoney F., Kane M., Margolis H., Hepatitis B Vaccine. Vaccines 2004, 299-337. Saunders Elsevier, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
28. World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/Gen 93; 1993.
29. Käyhty H., Peltola H., Karanko V., Mäkelä P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983, 147:1100.
30. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984, 149:1034-1035.
31. Ostergaard L., Lebacq E., Poolman J., Maechler G., Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009, 27:161-168.
32. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
33. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
34. Halperin S.A., Diaz-Mitoma F., Dull P., Anemona A., Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 2010, 29:259-267.
35. Rennels M., King J., Ryall R., Manoff S., Papa T., Weddle A., et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002, 21:978-979.
36. Pace D., Pollard A.J., Meningococcal A. C,Y and W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 2007, 92:909-915.
37. Zepp F., Schmitt H., Cleerbout J., Verstraeten T., Schuerman L., Jacquet J. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009, 8:663-678.
38. Borrow R., Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev Vaccines 2009, 8:265-279.
39. Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17:154-159.
40. Díez-Domingo J., Cantarino M.V.P., Torrentí J.M.B., Sansano M.I.U., Rosich A.J., Merino A.H., et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 2010, 29:148-152.
41. Glode M.P., Robbins J.B., Liu T.Y., Gotschlich E.C., Orskov I., Orskov F. Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis 1977, 135:94-104.
42. Guirguis N., Schneerson R., Bax A., Egan W., Robbins J.B., Shiloach J., et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med 1985, 162:1837-1851.
43. Troncoso G., Sánchez S., Criado M.T., Ferreirós C.M. Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis. FEMS Immunol Med Microbiol 2002, 34:9-15.